Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Viardot

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Oncotarget|September 5, 2015
Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphomaJochen K Lennerz, Karl Hoffmann, Anna-Maria Bubolz, et al.
Ejhaem|September 2, 2022
Targetable alterations in primary extranodal diffuse large B-cell lymphomaStephanie E Weissinger, Rucha Dugge, Miriam Disch, et al.
Future Oncology (London, England)|April 1, 2020
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphomaAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
Haematologica|July 29, 2017
Loss-of-function but not dominant-negative intragenic <i>IKZF1</i> deletions are associated with an adverse prognosis in adult <i>BCR-ABL</i>-negative acute lymphoblastic leukemiaBenjamin Kobitzsch, Nicola Gökbuget, Stefan Schwartz, et al.
British Journal of Haematology|July 9, 2003
Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myelomaPeter Liebisch, Andreas Viardot, Nicole Bassermann, et al.
Trials|September 1, 2019
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trialLaila König, Martin Dreyling, Jan Dürig, et al.
The Lancet. Haematology|November 29, 2023
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approachPeter Dreger, Paolo Corradini, John G Gribben, et al.
Human Vaccines & Immunotherapeutics|September 1, 2023
Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediatedSascha d'Almeida, Sinisa Markovic, Patrick Hermann, et al.
BMC Cancer|June 30, 2021
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trialAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
Blood|January 13, 2016
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphomaAndreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Oncotarget|September 5, 2015
Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphomaJochen K Lennerz, Karl Hoffmann, Anna-Maria Bubolz, et al.
Ejhaem|September 2, 2022
Targetable alterations in primary extranodal diffuse large B-cell lymphomaStephanie E Weissinger, Rucha Dugge, Miriam Disch, et al.
Future Oncology (London, England)|April 1, 2020
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphomaAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
Haematologica|July 29, 2017
Loss-of-function but not dominant-negative intragenic <i>IKZF1</i> deletions are associated with an adverse prognosis in adult <i>BCR-ABL</i>-negative acute lymphoblastic leukemiaBenjamin Kobitzsch, Nicola Gökbuget, Stefan Schwartz, et al.
British Journal of Haematology|July 9, 2003
Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myelomaPeter Liebisch, Andreas Viardot, Nicole Bassermann, et al.
Trials|September 1, 2019
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trialLaila König, Martin Dreyling, Jan Dürig, et al.
The Lancet. Haematology|November 29, 2023
CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approachPeter Dreger, Paolo Corradini, John G Gribben, et al.
Human Vaccines & Immunotherapeutics|September 1, 2023
Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediatedSascha d'Almeida, Sinisa Markovic, Patrick Hermann, et al.
BMC Cancer|June 30, 2021
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trialAlexander Grunenberg, Lisa M Kaiser, Stephanie Woelfle, et al.
Blood|January 13, 2016
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphomaAndreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, et al.
Pageof 9